BrainRepair UG
Company
Primary tabs
About your organization / profile
The future of BrainRepair is now !
- We are the founders of BrainRepair UG (https://brainrepair.eu/)
- We are a German Start-up with EMA SME Qualification EMA/SME/357/15/R3
- We develop autologous (own) cord blood stem cell therapies in Europe/USA for the treatment of Pediatric brain injury
- Our product was granted ATMP-TEP Classification by EMA for Pediatric brain damage, hypoxic-ischemic encephalopathy, and cerebral palsy.
- We develop and market (own) cord blood stem cell treatments for
- The treatment of Pediatric brain injury
- Periventricular leukomalacia
- Neonatal encephalopathy
- Perinatal intracranial hemorrhage
- Pediatric stroke
- Cerebral palsy
- TBI
- SCI
What makes us unique?
- Worldwide first Orphan Drug Designation granted by the European Commission/EMA on October 14, 2016 for
- ‘Autologous mononuclear cells derived from human cord blood’ for the treatment of newborns suffering from:
- First successful autologous cell therapy of Cerebral palsy and coma in 2009 (Jensen et al., 2009; 2011; 2013)
http://dx.doi.org/10.1155/2013/951827 - First successful autologous cell therapy of Perinatal ischemic stroke during birth (Jensen and Hamelmann, 2016)
http://dx.doi.org/10.1155/2016/1717426 - First pre-clinical prevention of ‘spastic paresis’ in newborn rats after cerebral hypoxic-ischemia (Meier et al., 2006)
https://www.researchgate.net/publication/7333251
Network (0)
There are no organizations in the network.
There are currently no users in this organisation.
